Clinical Commander

Back to dossier
cardio.dvt.warfarin-induced-skin-necrosis.v1PRODUCTION
cardio.dvt.warfarin-induced-skin-necrosis.v1

Warfarin-induced skin necrosis (protein C/S deficiency unmasking)

cardiologyacuteadult
Hard-required inputs
0 / 10
Care setting:

Encounter flow

11/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Warfarin-induced skin necrosis = transient procoagulant state during warfarin first 3-10 days from kinetic mismatch (protein C falls in 6-8h vs factors II/IX/X over 24-72h); STOP warfarin immediately, reverse with vitamin K + FFP/4F-PCC, bridge with non-warfarin AC, hematology consult for thrombophilia workup, plan lifelong warfarin avoidance with DOAC alternative

Inputs
1
Actions
0
Advance rule
Set
Advance when

WISN framed as protein C-deficiency unmasking, not generic AC bleeding

Patient inputs (15)

Protein C activity assay — must be drawn AFTER warfarin washout (≥2 weeks) for accurate baseline; on-warfarin assays will be falsely low in everyone (warfarin suppresses protein C synthesis); deficient if <55% activity

Protein S activity assay — same caveat as protein C; deficient if free protein S antigen <60% or activity <55%; second most common WISN-associated thrombophilia

Middle-aged women (postmenopausal) at highest WISN risk; age informs DOAC choice and dose adjustment for long-term AC

WISN female-predominant (postmenopausal women > men) — modifies pre-test probability and screening priority

WISN typically days 3-10 of warfarin initiation; high loading dose ≥10 mg/d or absent heparin/LMWH bridge increases risk — both modifiable preventive errors

Concurrent therapeutic-dose heparin or LMWH for ≥5-7 days during warfarin loading covers the protein C kinetic gap → reduces WISN risk; absent or insufficient bridge is a key modifiable risk factor

INR at presentation — typically supratherapeutic (≥3.0) when WISN manifests because factor VII (short half-life) has fallen but functional anticoagulation has not yet replaced the lost protein C activity

Baseline platelets for AC bleeding risk; Hgb for transfusion if extensive necrosis with hemorrhage

Photo-documentation with anatomic marker (ruler, surgical pen demarcation) for serial monitoring of necrosis extension; baseline within 1 hour of recognition

eGFR for DOAC dosing (apixaban / rivaroxaban) and LMWH dosing; FFP volume tolerance

Factor V Leiden genetic test — genetic, NOT affected by warfarin; ~5% of European-ancestry population heterozygous; modest WISN risk modifier

Antithrombin activity — rare but possible WISN-associated thrombophilia; deficient if <60%; affects AC strategy (heparin/LMWH less effective if AT-deficient)

APS workup (anticardiolipin antibody, lupus anticoagulant, β2-glycoprotein-1) — APS is associated with skin necrosis and procoagulant state; if positive, AC strategy changes (warfarin INR 2-3 traditional but DOAC controversial in triple-positive APS per TRAPS Pengo Blood 2018)

Family history of protein C / S deficiency, factor V Leiden, or unexplained warfarin-related skin necrosis → high pre-test probability for WISN on first warfarin exposure; informs cascade screening

Prior unprovoked VTE or partial thrombophilia workup informs decision to AVOID warfarin entirely and use DOAC for long-term AC

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (4)

4 need judgement
  • informationallife_threateningextensive_warfarin_skin_necrosis_requiring_surgical_debridement_or_amputation
    WISN with extensive full-thickness necrosis on breast / thigh / buttock / abdomen / limb requiring surgical debridement, skin grafting, or rare amputation; mortality 15-30% if delayed recognition
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereprotein_c_or_s_deficiency_confirmed_lifetime_warfarin_avoidance_with_doac_transition
    Thrombophilia workup confirms protein C or protein S deficiency (or both) — lifelong warfarin avoidance mandated; transition to DOAC for long-term AC; cascade family screening initiated
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverethrombophilia_workup_positive_for_aps_with_wisn_paradox
    WISN occurs in patient subsequently diagnosed with antiphospholipid syndrome (APS) — paradox because warfarin INR 2-3 is the standard AC for APS but precipitated WISN; triple-positive APS especially complicated (TRAPS Pengo Blood 2018 — DOAC inferior for triple-positive APS)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverewisn_recognition_in_warfarin_naive_patient_with_high_loading_dose_and_no_bridge
    WISN occurs in warfarin-naive patient given high loading dose (≥10 mg/d) without heparin or LMWH bridge — modifiable preventive errors; SYSTEM-LEVEL root cause analysis warranted
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

INITIAL_WORKUPrequiredDrives risk stratification
Loading…

Recommended regimen

WISN — STOP warfarin, reverse with vitamin K + FFP/4F-PCC, bridge with heparin/LMWH/fondaparinux, transition to DOAC long-term, lifelong warfarin avoidance (ASH 2018; ACCP 2021)
axis: warfarin_induced_skin_necrosis_emergency_reversal_with_lifelong_doac_transition
Selected axis "WISN — STOP warfarin, reverse with vitamin K + FFP/4F-PCC, bridge with heparin/LMWH/fondaparinux, transition to DOAC long-term, lifelong warfarin avoidance (ASH 2018; ACCP 2021)" by default fallback (first axis)
  • phytonadione_vitamin_k1
    first line
    vitamin_k_antidote
    5-10 mg IV slow infusion over 30 min • IV • one-time, may repeat once at 12-24h if INR persistently elevated
    triggers: warfarin_induced_skin_necrosis_recognized, warfarin_supratherapeutic_inr_with_skin_lesion
    ASH 2018 (PMID 30482764); ACCP 2021 (PMID 34352295) — restores protein C activity within 6-24h via new hepatic synthesis; IV preferred over PO for emergency due to predictable absorption; avoid IM (hematoma risk on AC); slow IV to avoid anaphylactoid reaction
    rxcui 8308
  • fresh_frozen_plasma
    first line
    plasma_product_protein_c_source
    2-4 units (10-15 mL/kg) IV • IV • one-time, may repeat per clinical response
    triggers: warfarin_induced_skin_necrosis_with_active_extension, severe_protein_c_deficiency_suspected
    ASH 2018; ACCP 2021 — FFP contains all coagulation factors INCLUDING protein C and protein S; immediate replacement bridges the kinetic gap until vitamin K-driven hepatic synthesis recovers; volume load consideration in HF / renal failure
  • four_factor_prothrombin_complex_concentrate
    first line
    pcc_4factor_kcentra
    25-50 IU/kg IV (per INR-based protocol; max 5000 IU) • IV • one-time
    triggers: warfarin_induced_skin_necrosis_with_volume_overload_concern_or_urgent_reversal, severe_wisn_with_extensive_necrosis
    ASH 2018; ACCP 2021 — 4F-PCC (Kcentra) contains factors II/VII/IX/X PLUS protein C and protein S; rapid reversal of warfarin (faster than FFP); volume-sparing (preferred if HF / renal failure); thrombotic risk manageable in WISN context where reversal is the priority
    rxcui 1670383
  • unfractionated_heparin
    first line
    parenteral_heparin
    80 U/kg IV bolus then 18 U/kg/h titrated to aPTT 1.5-2.5× baseline • IV • continuous infusion
    triggers: wisn_recognized_with_active_vte_indication_for_ac, no_history_of_hit_or_negative_pf4_screen
    ASH 2018; ACCP 2021 — therapeutic UFH is the bridge AC during warfarin reversal in WISN; heparin/LMWH does not depend on protein C and provides immediate AC; avoid if any HIT history or concurrent thrombocytopenia (separate workup needed)
    rxcui 5224
  • enoxaparin
    first line
    lmwh
    1 mg/kg SC q12h (or 1.5 mg/kg SC daily); renal-adjusted to 1 mg/kg SC daily if CrCl <30 • SC • q12h
    triggers: wisn_recognized_with_active_vte_indication, no_history_of_hit, oral_intake_intact_or_renal_function_acceptable
    ASH 2018; ACCP 2021 — LMWH alternative bridge AC; convenient outpatient transition; renal-adjust if CrCl <30; avoid if HIT history
    rxcui 67108
  • fondaparinux
    second line
    factor_xa_inhibitor_synthetic
    7.5 mg SC daily (5 mg if <50 kg; 10 mg if >100 kg) • SC • daily
    triggers: wisn_with_concurrent_hit_history_or_heparin_avoidance, eGFR_above_30
    ASH 2018 — fondaparinux alternative bridge AC if heparin / LMWH contraindicated (HIT history); does not cross-react with HIT antibodies; avoid CrCl <30; no antidote
    rxcui 321208
  • apixaban
    first line
    doac_factor_xa_direct
    10 mg PO BID × 7 d → 5 mg PO BID (or 2.5 mg BID per FDA dose-reduction criteria) • PO • BID indefinite or per VTE duration plan
    triggers: wisn_resolved_transitioning_to_long_term_AC, protein_c_or_s_deficiency_confirmed, avoid_warfarin_lifelong
    ASH 2018; ACCP 2021 — DOAC of first choice for long-term AC in protein C / S deficiency to AVOID lifetime warfarin re-challenge; AMPLIFY (Agnelli NEJM 2013 PMID 23808982); preferred over warfarin to eliminate WISN recurrence risk
    rxcui 1364430
  • rivaroxaban
    first line
    doac_factor_xa_direct
    15 mg PO BID × 21 d → 20 mg PO daily with food (15 mg if CrCl 15-50) • PO • BID then daily indefinite
    triggers: wisn_resolved_doac_alternative_to_apixaban, protein_c_or_s_deficiency_confirmed, patient_preference_or_apixaban_unavailable
    ASH 2018; ACCP 2021 — alternative DOAC for long-term AC; EINSTEIN-DVT (Bauersachs NEJM 2010 PMID 21128814)
    rxcui 1114195
  • protein_c_concentrate_ceprotin
    rescue
    protein_c_concentrate_severe_deficiency
    60-80 IU/kg IV initially then 45 IU/kg q6h to maintain protein C activity ≥25% • IV • q6h initially
    triggers: severe_extensive_wisn_with_homozygous_protein_c_deficiency_or_severe_acquired_depletion, available_at_hemophilia_treatment_center
    ASH 2018; rare use case — protein C concentrate (Ceprotin) for severe homozygous protein C deficiency or severe acquired depletion with extensive necrosis; available only at specialized hemophilia centers
    rxcui 8834

outpatient playbook — drug actions (2)

  1. 1. maintenance apixaban or rivaroxaban
    rxcui 1364430
    apixaban 5 mg BID OR 2.5 mg BID extended-reduced after 6 mo per AMPLIFY-EXT (Agnelli NEJM 2013 PMID 23216615); OR rivaroxaban 20 mg daily with food OR 10 mg daily extended • PO • BID or daily
    trigger: Per VTE duration plan
    ASH 2018; ACCP 2021; AMPLIFY-EXT
  2. 2. pre-procedure DOAC interruption plan
    rxcui 1364430
    hold apixaban 24-48h pre-procedure (longer if high bleed risk + reduced renal function); resume 24h post-procedure if hemostasis adequate • PO • per procedure
    trigger: Procedure requiring AC interruption
    ACCP 2021 perioperative AC

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Painful erythematous indurated plaque on breast / thigh / buttock / abdomen on warfarin day 3-10 — pre-necrosis warning sign; STAT recognition prevents extension; Hemorrhagic bullae or full-thickness skin necrosis on warfarin days 3-10, areas with abundant subcutaneous fat — established WISN; emergent reversal; Warfarin initiated without heparin or LMWH bridge OR with high loading dose ≥10 mg/d in patient with known or suspected protein C / S deficiency.

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Warfarin-induced skin necrosis (protein C/S deficiency unmasking)** (cardio.dvt.warfarin-induced-skin-necrosis.v1).
Scope: Warfarin-induced skin necrosis = transient procoagulant state during warfarin first 3-10 days from kinetic mismatch (protein C falls in 6-8h vs factors II/IX/X over 24-72h); STOP warfarin immediately, reverse with vitamin K + FFP/4F-PCC, bridge with non-warfarin AC, hematology consult for thrombophilia workup, plan lifelong warfarin avoidance with DOAC alternative

No severity triggers fired against current inputs.

Plan

Regimen axis: **WISN — STOP warfarin, reverse with vitamin K + FFP/4F-PCC, bridge with heparin/LMWH/fondaparinux, transition to DOAC long-term, lifelong warfarin avoidance (ASH 2018; ACCP 2021)**.
1. phytonadione_vitamin_k1 5-10 mg IV slow infusion over 30 min IV one-time, may repeat once at 12-24h if INR persistently elevated (vitamin_k_antidote, first line) — ASH 2018 (PMID 30482764); ACCP 2021 (PMID 34352295) — restores protein C activity within 6-24h via new hepatic synthesis; IV preferred over PO for emergency due to predictable absorption; avoid IM (hematoma risk on AC); slow IV to avoid anaphylactoid reaction
2. fresh_frozen_plasma 2-4 units (10-15 mL/kg) IV IV one-time, may repeat per clinical response (plasma_product_protein_c_source, first line) — ASH 2018; ACCP 2021 — FFP contains all coagulation factors INCLUDING protein C and protein S; immediate replacement bridges the kinetic gap until vitamin K-driven hepatic synthesis recovers; volume load consideration in HF / renal failure
3. four_factor_prothrombin_complex_concentrate 25-50 IU/kg IV (per INR-based protocol; max 5000 IU) IV one-time (pcc_4factor_kcentra, first line) — ASH 2018; ACCP 2021 — 4F-PCC (Kcentra) contains factors II/VII/IX/X PLUS protein C and protein S; rapid reversal of warfarin (faster than FFP); volume-sparing (preferred if HF / renal failure); thrombotic risk manageable in WISN context where reversal is the priority
4. unfractionated_heparin 80 U/kg IV bolus then 18 U/kg/h titrated to aPTT 1.5-2.5× baseline IV continuous infusion (parenteral_heparin, first line) — ASH 2018; ACCP 2021 — therapeutic UFH is the bridge AC during warfarin reversal in WISN; heparin/LMWH does not depend on protein C and provides immediate AC; avoid if any HIT history or concurrent thrombocytopenia (separate workup needed)
5. enoxaparin 1 mg/kg SC q12h (or 1.5 mg/kg SC daily); renal-adjusted to 1 mg/kg SC daily if CrCl <30 SC q12h (lmwh, first line) — ASH 2018; ACCP 2021 — LMWH alternative bridge AC; convenient outpatient transition; renal-adjust if CrCl <30; avoid if HIT history
6. fondaparinux 7.5 mg SC daily (5 mg if <50 kg; 10 mg if >100 kg) SC daily (factor_xa_inhibitor_synthetic, second line) — ASH 2018 — fondaparinux alternative bridge AC if heparin / LMWH contraindicated (HIT history); does not cross-react with HIT antibodies; avoid CrCl <30; no antidote
7. apixaban 10 mg PO BID × 7 d → 5 mg PO BID (or 2.5 mg BID per FDA dose-reduction criteria) PO BID indefinite or per VTE duration plan (doac_factor_xa_direct, first line) — ASH 2018; ACCP 2021 — DOAC of first choice for long-term AC in protein C / S deficiency to AVOID lifetime warfarin re-challenge; AMPLIFY (Agnelli NEJM 2013 PMID 23808982); preferred over warfarin to eliminate WISN recurrence risk
8. rivaroxaban 15 mg PO BID × 21 d → 20 mg PO daily with food (15 mg if CrCl 15-50) PO BID then daily indefinite (doac_factor_xa_direct, first line) — ASH 2018; ACCP 2021 — alternative DOAC for long-term AC; EINSTEIN-DVT (Bauersachs NEJM 2010 PMID 21128814)
9. protein_c_concentrate_ceprotin 60-80 IU/kg IV initially then 45 IU/kg q6h to maintain protein C activity ≥25% IV q6h initially (protein_c_concentrate_severe_deficiency, rescue) — ASH 2018; rare use case — protein C concentrate (Ceprotin) for severe homozygous protein C deficiency or severe acquired depletion with extensive necrosis; available only at specialized hemophilia centers

Setting playbook (outpatient) — Long-term management: AC continuation per VTE indication; LIFELONG warfarin avoidance; medical alert bracelet permanent; pre-procedure planning for any future surgery; family cascade screening completion; pregnancy planning if applicable
10. maintenance apixaban or rivaroxaban apixaban 5 mg BID OR 2.5 mg BID extended-reduced after 6 mo per AMPLIFY-EXT (Agnelli NEJM 2013 PMID 23216615); OR rivaroxaban 20 mg daily with food OR 10 mg daily extended PO BID or daily — Per VTE duration plan (ASH 2018; ACCP 2021; AMPLIFY-EXT)
11. pre-procedure DOAC interruption plan hold apixaban 24-48h pre-procedure (longer if high bleed risk + reduced renal function); resume 24h post-procedure if hemostasis adequate PO per procedure — Procedure requiring AC interruption (ACCP 2021 perioperative AC)

Non-pharmacologic actions:
- Pre-procedure plan documented before any anticipated surgery / hospitalisation
- Patient carries written WISN card
- Medical alert bracelet permanent
- Family + patient education repeatedly reinforced
- Pregnancy planning if applicable: switch to LMWH in pregnancy

AVOID / contraindication checks:
- Warfarin_absolutely_contraindicated_in_confirmed_protein_c_or_s_deficiency_use_doac_lifelong (ASH 2018)
- Warfarin_must_be_stopped_immediately_at_first_sign_of_wisn_painful_plaque_or_bullae (ASH 2018)
- Never_load_warfarin_with_10_mg_or_more_per_day_max_5_mg_start (Crowther 2003; ACCP 2016)
- Always_bridge_warfarin_initiation_with_heparin_or_lmwh_for_5_to_7_days (ACCP 2016)
- Vitamin_k_iv_slow_infusion_over_30_min_to_avoid_anaphylactoid_reaction (FDA label)
- Vitamin_k_avoid_im_route_due_to_hematoma_risk_on_ac (FDA label)
- Apixaban_dose_reduce_to_2.5_bid_if_2_or_more_of_age_above_80_weight_below_60_creatinine_above_1.5 (FDA label)
- Rivaroxaban_dose_reduce_to_15_daily_if_crcl_15_to_50 (FDA label)
- Doac_avoid_in_pregnancy_use_lmwh_for_vte_in_pregnancy_with_protein_c_or_s_deficiency (ASH 2018; ACOG 2018)
- Doac_caution_or_avoid_in_triple_positive_aps_per_traps_pengo_blood_2018 (use warfarin INR 2 3 in triple positive APS even though WISN risk; rigorous bridging mandatory)
- Decision:lifelong_warfarin_avoidance_in_protein_c_or_s_deficiency_with_doac_alternative (ASH 2018)
- Decision:medical_alert_bracelet_for_warfarin_intolerance_due_to_skin_necrosis (institutional safety practice)
- Decision:ehr_allergy_banner_for_warfarin (institutional safety practice)
- Decision:cascade_family_screening_for_protein_c_or_s_deficiency_in_first_degree_relatives (ASH 2018)
- Decision:hematology_referral_mandatory_for_thrombophilia_workup_after_warfarin_washout (ASH 2018)

Monitoring

Regimen monitoring:
- serial skin lesion photos with anatomic demarcation q4 to 12h until stable (clinical)
- daily inr until below 1.5 after reversal (FDA label)
- daily aptt or anti xa during heparin or lmwh bridge (FDA label)
- daily cbc and bmp (clinical)
- thrombophilia workup drawn after 2 weeks warfarin washout (ASH 2018)
- wound surveillance for infection during necrosis recovery (clinical)
- pain control with acetaminophen avoid nsaids (clinical)
- long term doac monitoring quarterly creatinine and cbc during first year (FDA label)
- annual ac continuation decision with hasbled reassessment (ACCP 2021)
- family cascade screening at diagnosis confirmation then annually until complete (ASH 2018)
- medical alert bracelet review at every visit (institutional)

Setting (outpatient) monitoring:
- Annual labs + clinical reassessment
- Annual HAS-BLED
- Family cascade screening completion documented

Follow-up plan: Hematology long-term follow-up; thrombophilia results review at 4 weeks; ≥3 mo AC for VTE indication (longer if ongoing risk); LIFELONG warfarin avoidance education with medical alert bracelet and EHR allergy banner; cascade family screening for protein C / S deficiency; pregnancy planning if applicable (DOAC contraindicated in pregnancy → LMWH for VTE in pregnancy with protein C / S deficiency)
- Close-out criterion: lifelong avoidance education + family screening + AC plan finalised

Monitoring phase: Serial skin photos with demarcation q4-12h until stable; daily CBC + BMP; weekly INR if any warfarin remaining (should be off); PTT if on UFH bridge; bleed surveillance; infection surveillance for necrotic wound; pain control

Disposition

Current setting: outpatient — Long-term management: AC continuation per VTE indication; LIFELONG warfarin avoidance; medical alert bracelet permanent; pre-procedure planning for any future surgery; family cascade screening completion; pregnancy planning if applicable

Disposition criteria:
- Indefinite annual follow-up; lifelong warfarin avoidance documented across all healthcare systems; family screening completed

Escalation triggers (move to higher acuity):
- New VTE despite DOAC → reassess adherence + consider switch (apixaban ↔ rivaroxaban) + reinvestigate thrombophilia
- Inadvertent warfarin re-exposure → STAT INR + clinical observation + reinforce avoidance
- Pregnancy → switch to LMWH (DOAC and warfarin both contraindicated; LMWH preferred per ASH 2018 pregnancy)
- Major bleed → reverse (andexanet alfa for apixaban / rivaroxaban — Connolly NEJM 2019 PMID 30730782; or PCC), hold, reassess indefinite indication

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] WISN with extensive full-thickness necrosis on breast / thigh / buttock / abdomen / limb requiring surgical debridement, skin grafting, or rare amputation; mortality 15-30% if delayed recognition
- [SEVERE] Thrombophilia workup confirms protein C or protein S deficiency (or both) — lifelong warfarin avoidance mandated; transition to DOAC for long-term AC; cascade family screening initiated
- [SEVERE] WISN occurs in patient subsequently diagnosed with antiphospholipid syndrome (APS) — paradox because warfarin INR 2-3 is the standard AC for APS but precipitated WISN; triple-positive APS especially complicated (TRAPS Pengo Blood 2018 — DOAC inferior for triple-positive APS)

Citations

- ASH 2018 Thrombophilia Guideline (Bates) + ACCP/CHEST 2021 (Stevens) for VTE treatment + ACCP 2016 (Kearon) for warfarin overlap principles [PMID:30482764](https://pubmed.ncbi.nlm.nih.gov/30482764/)
- Cited evidence (PMID 34352295) [PMID:34352295](https://pubmed.ncbi.nlm.nih.gov/34352295/)
- Cited evidence (PMID 33007077) [PMID:33007077](https://pubmed.ncbi.nlm.nih.gov/33007077/)
- Cited evidence (PMID 23808982) [PMID:23808982](https://pubmed.ncbi.nlm.nih.gov/23808982/)
- Cited evidence (PMID 23216615) [PMID:23216615](https://pubmed.ncbi.nlm.nih.gov/23216615/)

Last reconciled with current guidelines: 2026-05-15.
References
  • ASH 2018 Thrombophilia Guideline (Bates) + ACCP/CHEST 2021 (Stevens) for VTE treatment + ACCP 2016 (Kearon) for warfarin overlap principles — PMID:30482764
  • Cited evidence (PMID 34352295) — PMID:34352295
  • Cited evidence (PMID 33007077) — PMID:33007077
  • Cited evidence (PMID 23808982) — PMID:23808982
  • Cited evidence (PMID 23216615) — PMID:23216615